Ultime notizie per MAIA Biotechnology (AMEX:MAIA) Azioni

MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

MAIA Biotechnology Inc

Barclays analyst Lauren Lieberman maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Underweight and lowers the price target from $86 to $85.

News

Price Target

Analyst Ratings

Barclays Maintains Underweight on Church & Dwight Co, Lowers Price Target to $85

Guidance

Restaurant Brands International Executive Says Expect FY System-Wide Sales Growth Will Come In Slightly Below Expectations Laid Out In August; In China, Actively Working To Find Right Long-Term Path For Burger King

Barclays analyst Anthony Powell maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Underweight and raises the price target from $112 to $123.

Barclays Maintains Underweight on Choice Hotels Intl, Raises Price Target to $123

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/04/final-trades-starbucks-freeport-mcmoran-constellation-energy-and-the-xlu.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said he is keeping an eye on Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>). The stock is expected to make another run at $100, he added.
On Oct. 30, Starbucks reported weaker-than-expected fourth-quarter results. The company posted quarterly earnings of 80 cents per share which missed the analyst consensus estimate of $1.03 per share. The company reported quarterly sales of $9.074 billion which missed the analyst consensus <a href="https://www.benzinga.com/news/earnings/24/10/41634203/starbucks-likely-to-report-lower-quarterly-earnings-these-most-accurate-analysts-revise-forecasts-a">estimate of $9.375 billion.</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Shannon Saccocia of NB Private Wealth named The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) as <a href="https://www.benzinga.com/quote/XLU">her final trade.</a>
Sarat Sethi of DCLA named Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) as his final trade.
On Oct. 22, Freeport-McMoRan reported third-quarter FY24 results. Revenue stood at $6.79 billion, beating the consensus of $6.47 billion. Copper sales totaled 1.0 billion pounds, down 7% Y/Y and 2% above the July 2024 estimate, due to the timing of shipments and lower ore grades and operating rates in North America.
Joseph M. Terranova of Virtus Investment Partners picked Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), which pulled back on Monday.
On Nov. 4, Constellation Energy reported third-quarter results and revised its FY24 adjusted EPS guidance, which is below estimates.
Price Action:
<ul>
<li>The Utilities Select Sector SPDR Fund fell 1.2% during Monday's session.</li>
<li>Starbucks shares fell 1.9% to settle at $97.03 during Monday's session.</li>
<li>Freeport-McMoRan shares gained 1.5% to close at $46.27 on Monday.</li>
<li>Constellation Energy shares fell 12.5% to settle at $225.95 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

SBUX

Starbucks, Freeport-McMoRan, Constellation Energy And More On CNBC's 'Final Trades'

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Barclays analyst Michael Leithead maintains Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) with a Equal-Weight and raises the price target from $21 to $23.

Barclays Maintains Equal-Weight on Chemours, Raises Price Target to $23

<a href="https://www.benzinga.com/topic/2024-election">Election Day has arrived</a>, and we could all probably use a deep breath. Take a moment if you need it.
Now, onto the cannabis front where voters in Nebraska, North Dakota, South Dakota and Florida <a href="https://www.benzinga.com/markets/cannabis/24/10/41387752/winding-road-to-cannabis-legalization-ahead-for-4-states-set-to-vote-in-2024-what-do-the-polls-s">will decide on ballot initiatives</a> to legalize marijuana for recreational or medical use. If approved, these states will join the 38 others that have embraced some form of cannabis legalization and join the rapidly changing landscape of <a href="https://www.benzinga.com/topic/cannabis-reform">marijuana policy</a> in the U.S.
Here's what&#8217;s changed in the landscape…some might even say drastically.
<h3 class="wp-block-heading">One Of Our Favorites: Adult Weed Consumption Rises As Teen Use Falls</h3>
Concerns over a spike in youth cannabis consumption following early legalization efforts, beginning with Colorado and Washington in 2012, have proven unfounded. Contrary to fears, marijuana use among teens has declined, or maybe never really took off.
From 2011 to 2021, the <a href="https://www.benzinga.com/topic/cannabis-reform">percentage of adolescents reporting marijuana use</a> dropped from 23% to under 16%.
"The ‘sky's going to fall' scenario was that all of the kids were just going to have access to all of the cannabis and it was going to be a terrible, terrible thing," said Ryan Vandrey, professor of psychiatry and behavioral sciences at Johns Hopkins Medicine who studies cannabis.
"It just goes to show that teenagers will do exactly the opposite of what you think they're going to do at all times," Vandrey <a href="https://www.nytimes.com/2024/11/04/well/weed-cannabis-america.html">told</a> The New York Times, confirming what every parent who has or is raising a teenager already knows.
Adult cannabis consumption, meanwhile, <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">has reached historic highs</a>, with 42% of individuals aged 19-30 and 29% of those aged 35-50 reporting use in the past year.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41609840/sharp-drop-in-teen-marijuana-use-legalization-and-demographics-examined">Sharp Drop In Teen Marijuana Use: Legalization And Demographics Examined</a>
<h3 class="wp-block-heading">Cannabis Use Surpasses Alcohol</h3>
Yeah, you read that right. Recent studies have show that more Americans are now consuming <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">weed daily rather than alcohol</a>. Nearly 18 million people report daily or near-daily marijuana use, outpacing the 15 million who drink with similar frequency. 
<h3 class="wp-block-heading">Seniors Jump On The Weed Wagon Because…Why Not?</h3>
The country&#8217;s 73 million baby boomers are among the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/23/08/33583433/baby-boomers-turning-to-weed-en-masse-say-it-improves-memory-and-mood-doctors-agree-cnn-series-e" target="_blank" rel="noreferrer noopener">fastest-growing demographic</a><a href="https://www.benzinga.com/markets/cannabis/24/01/36458087/senior-cannabis-consumers-balancing-act-relief-for-numerous-conditions-comes-with-warnings-but-w" target="_blank" rel="noreferrer noopener">&nbsp;</a>of&nbsp;cannabis users in the U.S. and around the world. In the past 8 years, senior cannabis consumption has tripled. Seniors also happen to&nbsp;possess&nbsp;half of the nation's&nbsp;$140 trillion&nbsp;in wealth, so they&#8217;re helping the economy even after they&#8217;ve retired.
<h3 class="wp-block-heading">Closing That Gender Gap </h3>
Cannabis use has long been more prevalent among men than women, but that disparity is shrinking. In 2023, young women (ages 19-30) <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">reported higher rates of cannabis use</a> than their male counterparts. Teenage girls also now report higher marijuana use than boys, marking a shift in gender patterns of cannabis consumption.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41726320/hemp-donations-fuel-desantis-and-florida-gops-charge-against-weed-legalization-new-findings">Hemp Donations Fuel DeSantis And Florida GOP&#8217;s Charge Against Weed Legalization, New Findings</a></li>
</ul>
Photo: Shutterstock

Cannabis

Government

Politics

Legal

Election Day 2024: Will Florida, Nebraska, North And South Dakota Join The Marijuana Revolution?

Barclays analyst Tom O'Malley maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Overweight and raises the price target from $70 to $87.

ALAB

Barclays Maintains Overweight on Astera Labs, Raises Price Target to $87

Barclays analyst Julian Mitchell maintains APi Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) with a Overweight and raises the price target from $43 to $44.

Barclays Maintains Overweight on APi Gr, Raises Price Target to $44

KITT

Nauticus Robotics Secures Agreement To Convert $33M Debt Into Equity Via Preferred Stock Exchange, Aiming To Deleverage Balance Sheet And Address Nasdaq Compliance

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Ceva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) is &#8220;way too high, and I think you <a href="https://www.benzinga.com/quote/CEVA">should take something off the table.&#8221;</a>
Ceva will announce results for the third quarter on Nov. 7, 2024, before the opening bell.
&#8220;I love space stuff, and that's why I keep recommending Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). If there's going to be something in space, it is going to be done by Elon Musk."
Intuitive Machines will release its financial results for the third quarter on Thursday, Nov. 14, before the market opens.
When asked about Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), &#8220;I want so badly for the company to do well, but I can't recommend the stock.&#8221;
The company is reportedly set to pause production of its F-150 Lightning from mid-November until the year&#8217;s end, citing weaker-than-anticipated demand for the electric pickup, Automotive News reported.
&#8220;They are in the oil service business, and oil is not a growth commodity. So, I'm going to say you can't own the stock here, as much as I really like them,&#8221; the &#8220;Mad Money&#8221; host said when asked about SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
The company, last week, disclosed that its OneSubsea joint venture won a contract from BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) for a subsea boosting system as part of the greenfield development of the Kaskida project in the deepwater U.S.
Cramer recommended taking something off the table, when asked about Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>).
Vistra will replace The AES Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) in the Dow Jones Utility Average, effective prior to the open of trading on Friday, Nov. 8.
Price Action:
<ul>
<li>CEVA shares fell 0.2% to settle at $23.64 on Monday.</li>
<li>Intuitive Machines shares fell 6.5% to close at $7.58 on Monday.</li>
<li>Ford shares gained 1.4% to settle at $10.36 during the session.</li>
<li>SLB gained 1.4% to settle at $40.32 on Monday.</li>
<li>Vistra shares fell 3.2% to close at $115.74.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

CEVA

LUNR

TSLA

Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'

WIIM

DuPont shares are trading higher after the company reported better-than-expected Q3 EPS and raised its FY24 adjusted EPS guidance.

APLS

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Pfizer's Recent Short Interest

KKR's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) short percent of float has fallen 13.57% since its last report. The company recently reported that it has 11.63 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KKR Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KKR has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KKR's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KKR's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into KKR's Recent Short Interest

PDD Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NYSE">PDD</a>) short percent of float has fallen 7.83% since its last report. The company recently reported that it has 32.98 million shares sold short, which is 4.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PDD Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PDD Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PDD Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PDD Holdings's peer group average for short interest as a percentage of float is 9.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Looking Into PDD Holdings's Recent Short Interest

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

AHCO

AdaptHealth Corp shares are trading lower after the company reported worse-than-expected Q3 sales and revised its FY24 net revenue guidance

Cleveland-Cliffs shares are trading lower following worse-than-expected Q3 financial results.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MAIA Biotechnology (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/">MAIA</a>) just reported results for the first quarter of 2024.<ul><li>MAIA Biotechnology reported earnings per share of -46 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/maia-stock-earnings-maia-biotechnology-for-q1-of-2024/">MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024

ASTS, ALLO and CMCM are among premarket gainers

MAIA Biotechnology, Inc. (MAIA) has shared an update. MAIA Biotechnology, Inc. has announced promising results from its Phase 2 THIO-101 clinical t...

MAIA Biotechnology Unveils Promising THIO-101 Trial Results

Recent Run-Up Provides MAIA Biotechnology With Breathing Room

MAIA Biotechnology, Inc. (MAIA) has issued an announcement. MAIA Biotechnology, Inc. recently updated investors with a presentation and summary on ...

MAIA Biotechnology Highlights Clinical Progress and Investor Insights

An announcement from MAIA Biotechnology, Inc. (MAIA) is now available. MAIA Biotechnology, Inc. has announced significant year-to-date achievements...

MAIA Biotechnology Reports Progress in Cancer Drug Development

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MAIA Biotechnology (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/">MAIA</a>) just reported results for the second quarter of 2024.<ul><li>MAIA Biotechnology reported earnings per share of -40 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/maia-stock-earnings-maia-biotechnology-for-q2-of-2024/">MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024

MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an announcement. MAIA Biotechnology, Inc. is actively engaging with the financial community, presen...

MAIA Biotechnology Advances with Clinical Trials and Partnerships

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), with ...

Noble Financial Reaffirms Their Buy Rating on MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology prices $2.44M private placement

AGBA

ALLO

ASTS

BCAN

CMCM

EDBL

MAIA

MNDR

SILO

Screenshot 2024-09-10 at 8.49.39 PM

Biotech

General

REGN

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Screenshot 2024-06-06 at 5.43.20 PM

New Clinical Data Reveals MAIA Biotechnology&#39;s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Screenshot 2024-05-21 at 5.35.44 PM

MAIA Biotechnology&#39;s Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Screenshot 2024-02-28 at 6.41.05 PM

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Press Releases

MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO

New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

MAIA Biotechnology Announces $2.44 Million Private Placement

ADMA

BMRN

CORT

EXEL

GMAB

HALO

INCY

JAZZ

MDXG

TECH

UTHR

VRTX

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Coherus BioSciences

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

IO Biotech

Kronos Bio

Metagenomi

Monopar Therapeutics

Mural Oncology

Omega Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

RAPT Therapeutics

Serina Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Comments

MAIA Biotechnology

Notizie

Ultime notizie per MAIA Biotechnology (AMEX:MAIA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO